ATRA Syndrome:10 year experience

Detalhes bibliográficos
Autor(a) principal: Pinheiro, Ronald Feitosa
Data de Publicação: 2003
Outros Autores: Pelloso, Luis Arthur Flores, Yamamoto, Mihoko, Chauffaille, Maria de Lourdes Lopes Ferrari, Bordim, José Orlando
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/2120
Resumo: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) responsible for 10% of all AMLs. Usually, the treatment of APL consists of chemotherapy and all-trans retinoic acid (ATRA) administration. The major side effect of ATRA is the socalled "ATRA syndrome", which has an incidence of nearly 30%. We studied the clinical presentation and the incidence of ATRA syndrome in patients with APL admitted to Hospital São Paulo-UNIFESP-EPM. Thirteen patients with APL received ATRA. ATRA syndrome was diagnosed in 5 patients (38%) with a mean age of 29 years old, which were, in average, in the 10th day of the use of ATRA. The most frequent clinical findings were respiratory distress, pulmonary infiltrate on chest X-Ray and fever. This report calls attention to the need of early diagnosis of the syndrome with prompt introduction of dexamethasone at the first sign in order to obtain therapeutic success.
id INCA-1_747dee00567cbe5690767a892f586411
oai_identifier_str oai:rbc.inca.gov.br:article/2120
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling ATRA Syndrome:10 year experienceSíndrome Atra: experiência de 10 anosLeucemia Promielocítica AgudaDiagnósticoQuimioterapiaÁcido TransretinóicoSíndrome ATRAAcute Promyelocytic LeukemiaDiagnosisChemotherapyAll-Trans Retinoic AcidATRA SyndromeAcute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) responsible for 10% of all AMLs. Usually, the treatment of APL consists of chemotherapy and all-trans retinoic acid (ATRA) administration. The major side effect of ATRA is the socalled "ATRA syndrome", which has an incidence of nearly 30%. We studied the clinical presentation and the incidence of ATRA syndrome in patients with APL admitted to Hospital São Paulo-UNIFESP-EPM. Thirteen patients with APL received ATRA. ATRA syndrome was diagnosed in 5 patients (38%) with a mean age of 29 years old, which were, in average, in the 10th day of the use of ATRA. The most frequent clinical findings were respiratory distress, pulmonary infiltrate on chest X-Ray and fever. This report calls attention to the need of early diagnosis of the syndrome with prompt introduction of dexamethasone at the first sign in order to obtain therapeutic success.A leucemia promielocítica aguda (LPA) é um subtipo de leucemia mielóide aguda (LMA) responsável por 10% de todas as LMAs. Geralmente, o tratamento da LPA consiste de quimioterapia e uso de ácido transretinóico (ATRA). O maior efeito colateral do ATRA é a "Síndrome ATRA", que ocorre com uma freqüência de quase 30%. Estudamos a apresentação clínica e a incidência da Síndrome ATRA em pacientes com LPA admitidos no Hospital São Paulo (da Escola Paulista de Medicina-UNIFESP). Treze pacientes com LPA fizeram uso de ATRA. A síndrome foi diagnosticada em cinco pacientes (38%) com idade média de 29 anos e que estavam,em média, no décimo dia do uso de ATRA. Os achados clínicos mais freqüentes foram insuficiência respiratória, infiltrado pulmonar à radiografia e febre. Este relato chama a atenção para a necessidade do diagnóstico precoce dessa síndrome, com a introdução de dexametasona ao primeiro sinal no intuito de êxito terapêutico.INCA2003-03-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/212010.32635/2176-9745.RBC.2003v49n1.2120Revista Brasileira de Cancerologia; Vol. 49 No. 1 (2003): Jan./Feb./Mar; 27-31Revista Brasileira de Cancerologia; Vol. 49 Núm. 1 (2003): ene./feb./mar.; 27-31Revista Brasileira de Cancerologia; v. 49 n. 1 (2003): jan./fev./mar.; 27-312176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/2120/1315Pinheiro, Ronald Feitosa Pelloso, Luis Arthur Flores Yamamoto, Mihoko Chauffaille, Maria de Lourdes Lopes Ferrari Bordim, José Orlando info:eu-repo/semantics/openAccess2021-11-29T20:36:15Zoai:rbc.inca.gov.br:article/2120Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:36:15Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv ATRA Syndrome:10 year experience
Síndrome Atra: experiência de 10 anos
title ATRA Syndrome:10 year experience
spellingShingle ATRA Syndrome:10 year experience
Pinheiro, Ronald Feitosa
Leucemia Promielocítica Aguda
Diagnóstico
Quimioterapia
Ácido Transretinóico
Síndrome ATRA
Acute Promyelocytic Leukemia
Diagnosis
Chemotherapy
All-Trans Retinoic Acid
ATRA Syndrome
title_short ATRA Syndrome:10 year experience
title_full ATRA Syndrome:10 year experience
title_fullStr ATRA Syndrome:10 year experience
title_full_unstemmed ATRA Syndrome:10 year experience
title_sort ATRA Syndrome:10 year experience
author Pinheiro, Ronald Feitosa
author_facet Pinheiro, Ronald Feitosa
Pelloso, Luis Arthur Flores
Yamamoto, Mihoko
Chauffaille, Maria de Lourdes Lopes Ferrari
Bordim, José Orlando
author_role author
author2 Pelloso, Luis Arthur Flores
Yamamoto, Mihoko
Chauffaille, Maria de Lourdes Lopes Ferrari
Bordim, José Orlando
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Pinheiro, Ronald Feitosa
Pelloso, Luis Arthur Flores
Yamamoto, Mihoko
Chauffaille, Maria de Lourdes Lopes Ferrari
Bordim, José Orlando
dc.subject.por.fl_str_mv Leucemia Promielocítica Aguda
Diagnóstico
Quimioterapia
Ácido Transretinóico
Síndrome ATRA
Acute Promyelocytic Leukemia
Diagnosis
Chemotherapy
All-Trans Retinoic Acid
ATRA Syndrome
topic Leucemia Promielocítica Aguda
Diagnóstico
Quimioterapia
Ácido Transretinóico
Síndrome ATRA
Acute Promyelocytic Leukemia
Diagnosis
Chemotherapy
All-Trans Retinoic Acid
ATRA Syndrome
description Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) responsible for 10% of all AMLs. Usually, the treatment of APL consists of chemotherapy and all-trans retinoic acid (ATRA) administration. The major side effect of ATRA is the socalled "ATRA syndrome", which has an incidence of nearly 30%. We studied the clinical presentation and the incidence of ATRA syndrome in patients with APL admitted to Hospital São Paulo-UNIFESP-EPM. Thirteen patients with APL received ATRA. ATRA syndrome was diagnosed in 5 patients (38%) with a mean age of 29 years old, which were, in average, in the 10th day of the use of ATRA. The most frequent clinical findings were respiratory distress, pulmonary infiltrate on chest X-Ray and fever. This report calls attention to the need of early diagnosis of the syndrome with prompt introduction of dexamethasone at the first sign in order to obtain therapeutic success.
publishDate 2003
dc.date.none.fl_str_mv 2003-03-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/2120
10.32635/2176-9745.RBC.2003v49n1.2120
url https://rbc.inca.gov.br/index.php/revista/article/view/2120
identifier_str_mv 10.32635/2176-9745.RBC.2003v49n1.2120
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/2120/1315
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 49 No. 1 (2003): Jan./Feb./Mar; 27-31
Revista Brasileira de Cancerologia; Vol. 49 Núm. 1 (2003): ene./feb./mar.; 27-31
Revista Brasileira de Cancerologia; v. 49 n. 1 (2003): jan./fev./mar.; 27-31
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042249521954816